Ibnsina Pharma (EGX:ISPH)

Egypt · Delayed Price · Currency is EGP

10.33

-0.04 (-0.39%)

At close: Nov 12, 2026

Market Cap	10.41B -2.9%
Revenue (ttm)	83.04B +22.0%
Net Income	870.32M +37.4%
EPS	0.86 +37.4%
Shares Out	1.01B
PE Ratio	11.96
Forward PE	7.93
Dividend	0.16 (1.55%)
Ex-Dividend Date	Oct 12, 2026

Volume	3,379,985
Open	10.37
Previous Close	10.37
Day's Range	10.26 - 10.47
52-Week Range	9.02 - 16.93
Beta	0.77
Analysts	Strong Buy
Price Target	16.51 (+59.83%)
Est. Earnings	Nov 19, 2026

About Ibnsina Pharma

Ibnsina Pharma operates as a pharmaceutical distributor in Egypt. The company offers pharmaceutical and cosmetics products to private and public-sector customers, including retail chains, independent pharmacies, wholesalers, hospitals, and healthcare institutions. It also provides warehousing and logistics services for its suppliers; marketing solutions; importation and packaging services; and market research and analysis services, as well as telesales and promotion services. The company was founded in 2001 and is headquartered in El Obour City... [Read more]

Industry Drugs, Drug Proprietaries, and Druggists' Sundries

Founded 2001

Employees 5,500

Stock Exchange Egyptian Stock Exchange

Ticker Symbol ISPH

Full Company Profile

Financial Performance

In 2025, Ibnsina Pharma's revenue was 76.60 billion, an increase of 37.17% compared to the previous year's 55.84 billion. Earnings were 771.11 million, an increase of 54.90%.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for ISPH stock is "Strong Buy." The 12-month stock price target is E£16.51, which is an increase of 59.83% from the latest price.

Price Target

E£16.51

(59.83% upside)

Analyst Consensus: Strong Buy

Stock Forecasts